Clinical application of gene expression analysis in patients with insect venom allergy

Completed

• Conditions: Hymenoptera allergy; insect venom allergy; 10001708

• Registration Number: NL-OMON33607
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

Inclusion criteria are the diagnosis of insect venom allergy based on medical history (grade IV according to Mueller before VIT), positive skin tests or sIgE and exclusion of mastocytosis

Exclusion Criteria

Exclusion criteria are lack of consent, pregnancy, severe chronic or/and malignant disease, mastocytosis

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main parameter of the study is the gene expression profile which may<br /><br>predict the long term effect of venom immunotherapy.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>1. The secondary parameter is the gene expression profile which will be<br /><br>specific for patients with the highest risk at a systemic reaction at a resting<br /><br>* before insect venom immunotherapy?<br /><br>2. The tertiary parameter is the gene expression profile specific for patients<br /><br>with the lowest risk of the systemic reaction to insect sting at the end of<br /><br>maintenance phase of VIT?</p><br>